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Objective: Assess current clinical practices for uveal melanoma (UM) and the impact of
molecular prognostic testing on treatment decisions.
Design: Cross-sectional survey and sequential medical records review.
Participants: Ophthalmologists who treat UM.
Methods: (A) Medical records review of all Medicare beneficiaries tested by UM gene expression profile in 2012, conducted under an institutional review board-approved protocol. (B) 109
ophthalmologists specializing in the treatment of UM were invited to participate in 24-question
survey in 2012; 72 were invited to participate in a 23-question survey in 2014.
Main outcome measures: Responses analyzed by descriptive statistics, frequency analyses
(percentages, Tukey, histograms), and Fisher’s exact test. Descriptive presentation of essay
answers.
Results: The review of Medicare medical records included 191 evaluable patients, 88 (46%)
with documented medical treatment actions or institutional policies related to surveillance
plans. Of these 88, all gene expression profiling (GEP) Class 1 UM patients were treated with
low-intensity surveillance. All GEP Class 2 UM patients were treated with high-intensity
surveillance (P0.0001 versus Class 1). There were 36 (19%) with information concerning
referrals after initial diagnosis. Of these 36, all 23 Class 2 patients were referred to medical
oncology; however, none of the 13 Class 1 patients were referred (P0.0001 versus Class 1).
Only Class 2 patients were recommended for adjunctive treatment regimens. 2012 survey: 50
respondents with an annual median of 35 new UM patients. The majority of respondents (82%)
performed molecular analysis of UM tumors after fine needle biopsy (FNAB); median: 15
FNAB per year; 2014 survey: 35 respondents with an annual median of 30 new UM patients.
The majority offered molecular analyses of UM tumor samples to most patients. Patients with
low metastatic risk (disomy 3 or GEP Class 1) were generally assigned to less frequent (every
6 or 12 months) and less intensive clinical visits. Patients with high metastatic risk (monosomy
3 or GEP Class 2) were assigned to more frequent surveillance with hepatic imaging and liver
function testing every 3–6 months. High-risk patients were considered more suitable for adjuvant treatment protocols.
Conclusion: The majority of ophthalmologists treating UM have adopted molecular diagnostic
tests for the purpose of designing risk-appropriate treatment strategies.
Keywords: uveal melanoma, gene expression profiling (GEP), medicare, molecular diagnostic test

Introduction
The most common primary intraocular cancer in the United States is uveal melanoma
(UM), the second most frequent subcategory of melanoma.1 New UM cases occur at
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a rate of ~4.3 per million per year; UM has the distinction of
being one of the few clinically-diagnosed malignancies.1–5 In
addition, tumor tissue is rarely archived, because the majority
of UM patients receive eye-sparing treatment of the primary
tumor. Unfortunately, although less than 4% of patients have
detectable metastatic disease at the time of initial diagnosis,
~50% will eventually manifest distant tumors, primarily in
the liver. Traditional staging methods that use clinical and
histologic prognostic factors, such as the American Joint
Committee on Cancer (AJCC) TNM system, can be used
to stratify patients into general risk categories, but they do
not provide sufficient predictive accuracy to be used for
patient care.6 Based on AJCC and National Comprehensive
Cancer Network (NCCN)7 cancer management guidelines,
a 50% risk of metastasis (or recurrence) generally correlates
with Stage III disease, the closest example being cutaneous melanoma, and stage III disease is uniformly treated
with high-intensity imaging and, when available, adjuvant
chemotherapy, targeted therapy, or radiotherapy. Given
the poor accuracy of the TNM staging system for UM, the
management of UM patients has been historically variable,
owing to the lack of clearly defined treatment guidelines.
As a consequence, management of all patients as high-risk
for tumor metastasis in some clinical practices may result
in overmanagement of patients who were actually low-risk.
Conversely, in other clinical practices, high-risk patients may
be relatively undermanaged.
Loss of chromosome 3 is one of the key early cytogenetic alterations associated with more aggressive UM,8 and
monosomy of chromosome 3 in as little as 6% of tumor
cells significantly increases the risk of UM metastasis.9
However, intratumoral heterogeneity for monosomy 3 is a
frequent occurrence that complicates accurate detection and
is understandable, given that the majority of tumor specimens
are obtained from a single pass fine-needle aspiration biopsy
(FNAB).10–12 This FNAB approach is further complicated
by the need for relatively large tumor samples, in order to
perform the most common chromosomal detection methods,
such as fluorescent in situ hybridization (FISH). As a result,
technical failure in FNAB specimens has been reported in
as many as 50% of cases.13–15
More recently, gene expression profiling (GEP) of UM has
gained diagnostic acceptance among ocular oncologists.3,4,16
GEP takes a “snapshot” of the tumor microenvironment that
can be used to predict the metastatic potential of the tumor.
Because tumor sample requirements are generally lower for
GEP assay, it has a lower technical failure rate than chromosomal assays.17 GEP has been reported in multicenter
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studies to have superior predictive results versus clinical,
pathological, or chromosomal analyses. 3,4,8,16
Molecular analysis of UM requires FNAB samples.
However, few reports exist in the medical literature documenting the specific FNAB practices used by ocular oncologists in UM patients. Even though molecular testing has been
concluded to be a clinically significant prognostic factor,
recommended by the AJCC,18 there are few data documenting the current frequency and uses of molecular tests in
the UM patient population. The availability of validated,
accurate prognostic information may impact the selection
of a management or treatment plan, including surveillance,
referral, and therapy initiation within the clinic or clinical
trial environment that matches metastatic risk. The intent of
this investigation is to assess the current clinical practices
for UM and the impact of molecular prognostic testing on
treatment decisions through (1) focused surveys among
ophthalomologists who diagnose and treat UM patients,
and (2) a sequential review of limited medical records and
known documented policies for all Medicare beneficiaries
whose GEP tests were successfully performed and records
were available in 2012.

Methods
Medicare medical records review
A retrospective, treatment decision impact analysis of the
medical records of patients for whom UM GEP testing was
ordered and processed for routine clinical use in 2012 was
performed. These medical records were acquired by Castle
Biosciences, Inc., (Friendswood, TX) to fulfill Medicare
requirements for medical record submission during insurance claims submissions and appeals. The medical chart
records were limited to the timeframe, including diagnosis
of UM through approximately 12 weeks following primary
eye tumor treatment. The Medicare patients had been treated
by one of 37 ophthalmologists in the US. Only data related
to basic demographics, UM tumor pathology and diagnosis,
clinical surveillance practices, and institutional treatment
policies were extracted from the records. Documented medical policy statements pertaining to use of prognostic testing
results were also included. This study was approved by the
Western Institutional Review Board, Olympia, WA. The
data were analyzed by descriptive statistics. Fisher’s exact
test was used to analyze the data for GEP Class versus 1)
surveillance intensity, 2) oncology referral rates, and 3)
adjuvant treatment.
For both the medical records review and the clinician
survey, high-intensity surveillance of UM patients was
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defined as clinical visits every 3–6 months, liver function
tests every 3–6 months, and liver imaging/systemic evaluation (eg, computed tomography [CT], ultrasound, magnetic
resonance imaging [MRI]) every 3–6 months. Low-intensity
surveillance of UM patients was defined as clinical visits
every 6–12 months and liver function tests, with or without
some type of hepatic imaging, once a year.

37 diagnosing physicians (Figure 1). The evaluable patient
cohort was 57% male with a mean age of 72±8 years (±
standard deviation). Fifty-eight percent of the patients were
GEP Class 1 and 42% were GEP Class 2. Of these cohorts,
91% of the Class 1 and 84% of the Class 2 tumor samples
were comprised of FNAB, with the remainder from formalinfixed, paraffin-embedded enucleation tissue.

Surveys of clinicians

Surveys of clinicians: general practices

Two surveys were performed, one in 2012 and the other
in 2013/14. In 2012, ocular oncologists (ophthalmologists
with subspecialty training in ocular oncology via retina,
ophthalmic pathology, or ocular oncology fellowships)
treating UM in North America, South America, and Europe
were invited to participate anonymously in a 24-question
survey that explored the use of FNAB and molecular
diagnostic tests in their clinical management of UM cases.
This survey was conducted in response to an invitation
from the American Association of Ophthalmologists to the
lead author (Thomas M Aaberg Jr) to give a plenary talk
on “Practical Approaches to Genetic Diagnosis for Ocular
Melanoma” at their 2012 retina subspecialty Day meeting
in Chicago, IL.
At the end of 2013/beginning of 2014, ocular oncologists treating UM in the US were invited to participate
anonymously in a 23-question survey that explored the use of
radiotherapy and molecular diagnostic testing of UM tumor
biopsies in current clinical practice. The follow-up study was
conducted to address topics not covered in the first survey, to
investigate whether or not any changing trends in patient care
could be detected, and to attempt to expand the respondent
pool. The invitees included all known ocular specialists in
practice at the time of each survey. The list of potential survey ocular oncologists was developed by referring to several
ophthalmology association membership listings and through
personal knowledge of the field by the authors, based on
practice patterns of clinicians who diagnosed and managed
UM patients. An online survey tool was used to capture
responses. The survey questions and data analyses were
developed by the authors. Survey responses were analyzed
by descriptive statistics and frequency analyses (percentages, Tukey, histograms), with descriptive presentation of
essay answers.

Fifty out of the 109 queried ocular oncologists participated in
the 2012 survey designed to assess the prevalence of FNAB
and molecular diagnostic tests for managing the treatment
of UM patients (46% response rate). The median annual
caseload of new UM patients for each ocular oncologist
was 35 (mean ± standard error of the mean [SEM]: 56±11)
(Figure 2A). The majority (82%) performed some type of
cellular and/or molecular analysis of UM cases, requiring
the use of tumor tissue FNAB. Eighty-seven percent of
respondents (32 out of 37) analyzed all biopsy tumor samples
from both FNAB and enucleated eyes, while the remainder
analyzed only enucleated eyes. Safety concerns relating to
tumor location or other features rendered a median of 10%
of the UM patients ineligible for a biopsy procedure across
the respondents’ clinical practices.
Thirty-five out of the 72 queried ocular specialists participated in the 2014 survey (49% response rate). Twelve (34%)
had not participated in the 2012 survey, seven (20%) were
unsure, and 16 (46%) had previously participated in the 2012
survey. Of the respondents, 49% were based at a university,
46% were based in private practice, and two (5%) were
based at both. The majority (66%) were the only physician
in their practice group to treat UM, with 29% indicating that
one other colleague in their practice group also treated UM,
and only two respondents indicating that two or more other
colleagues treated UM. The median annual caseload of new
UM patients for each ocular oncologist was 30 (mean ± SEM:
40±5) (Figure 2B). GEP was offered to patients by 88% of
respondents (30 out of 34), while 24% offered chromosome
three analysis (CHR3) (8 out of 34).

Results
Medicare medical records review
There were 191 evaluable Medicare medical records
(of 195 total beneficiaries tested) for UM patients treated by
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Surveys of clinicians: surgical techniques
and radiotherapy
As illustrated in Figure 2A, respondents in the 2012 survey
performed a median of 15 UM biopsies per year (mean:
27±7). Almost all (94%) were conducted at the time of plaque
placement, enucleation, or clip placement. Most respondents
biopsied only one site (69%), while 20% biopsied two sites.
Few biopsied more than two sites (11%).
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All successful
GEP tests
N=195
Records
not obtained
N=4
Evaluable
N=191

GEP Class 2
N=81
42%

GEP Class 1
N=110
58%

Records with
surveillance recommendation
N=88
Class 1
N=48
100% low
intensity

Class 2
N=40
100% high
intensity

Records with
medical oncology referral
information N=36

Class 1
N=13
0% referred to
medical
oncology

Class 2
N=23
100% referred to
medical
oncology

Records with
adjunctive treatment
recommendation N=8
Class 1
N=0
0%
recommended

Class 2
N=8
100%
recommended

Figure 1 Summary of Medicare medical records review.
Notes: There were 191 evaluable Medicare medical records for UM patients treated by 37 diagnosing physicians. High-intensity surveillance of UM patients was defined
as clinical visits every 3–6 months, liver function tests every 3–6 months, and liver imaging/systemic evaluation (eg, CT, ultrasound, MRI) every 3–6 months. Low-intensity
surveillance of UM patients was defined as clinical visits every 6–12 months and liver function tests, with some type of hepatic imaging, at least once a year.
Abbreviations: UM, uveal melanoma; CT, computed tomography; MRI, magnetic resonance imaging; GEP, gene expression profiling.
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or more of their surgeries. A median of 80% of biopsy procedures were performed transscleral (mean ± SEM: 70±5) and
a median of 20% were performed transvitreal (mean ± SEM:
30±5). Choice of approach was generally determined by tumor
location and depth, although several respondents indicated

Annual number of new UM cases

The majority of respondents in the 2012 survey used a 25
(57%) or 27 (43%) gauge needle for the FNAB, and 77% used
flexible tubing between the needle hub and a ten cc syringe, to
stabilize the needle. Most respondents (74%) did not use a vitrector for the biopsy procedure, although 9% used one for 50%
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Figure 2 Number of new UM cases and biopsy activity per responding physician, collected from the clinician surveys in 2012 (number of participating physicians (n) =50) and
early 2014 (number of participating physicians (n) =35).
Notes: Box plots with Tukey analysis. (A) Data derived from the 2012 survey: number of new UM cases per reporting physician (median: 35, mean: 56) and annual number
of biopsies (median: 15, mean: 27). (B) Data derived from the 2014 survey: number of new UM cases per reporting physician (median: 30, mean: 40).
Abbreviation: UM, uveal melanoma.
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better results in general whenever a transscleral approach
was possible. Very posterior tumors were more likely to be
approached transvitreally. There was almost an even split
between biopsy procedures performed via a scleral window
(57%) or via a full thickness sclera (43%). Approximately half
of respondents (54%) sealed the biopsy site, while the other
half did not. FNAB specimens were usually preserved in the
fixative kit provided by the testing lab (83%).
In the 2014 survey, when patients were amenable to radiotherapy, 94% of respondents used brachytherapy primarily or
exclusively (32 out of 34) and two used proton beam therapy.
Patients undergoing radiotherapy were offered some type of
molecular analysis of their pre-radiation tumor biopsy tissue
“nearly always” by 76% of respondents (N=35) (Figure 3A).
Four of the five respondents who “never or rarely” offered
molecular analysis cited safety concerns. Three stated that
the information would not alter their patients’ management,
and three respondents gave other reasons. One perceived the
biopsy procedure as technically difficult. One believed this
type of analysis should only be used in an investigational setting, not in routine clinical practice. The other respondent did
not believe the information would be useful to the patient.
Similar to the 2012 survey, a minority of UM patients
(median: 12.5%; mean: 22%±5%) in the 2014 survey were
considered ineligible for a tumor biopsy procedure, due to
safety concerns associated with the surgery, such as small
tumor size or tumor location (N=32). Of the remaining radiotherapy patients, for whom there was no biopsy safety concern and for whom cytogenetic or GEP analyses were offered,
a median of 90% agreed to testing (mean: 69%±6%). The
primary reasons for declining the tests were that the patient
did not want to know (65%; N=26), safety concerns about the

Surveys of clinicians: tumor biopsy
analyses
The majority of respondents (77%) in the 2012 survey offered
all patients a biopsy and some form of molecular tumor
analysis. Some of the reasons for not offering a biopsy and
testing included: 1) the tumor being too small and close to the
macula, 2) the lack of treatments proven to improve clinical
outcomes, 3) vision loss outweighing any potential benefits,
and 4) lack of coverage for the procedures by some medical insurance carriers. FNAB specimens were analyzed by
cytology (49%), chromosomal analysis (20%), and/or GEP
(89%) (Figure 4). Six percent were used only for research
purposes. Fourteen percent were preserved in a tissue bank
or used for a combination of research and other tests. Among
respondents to the 2012 survey, 19% offered CHR3 to most
of their UM patients; 13.5% offered CHR3 to all patients, and
the majority (65%) offered CHR3 to none of their patients
(Figure 5A). Seventy-eight percent of respondents offered
molecular testing using GEP analysis to most of their UM
patients; 54.1% offered GEP analysis to all patients, and
8% offered GEP analysis to none of their patients. The 2014
survey suggested a shift towards more respondents offering all their patients GEP and none of their patients CHR3
(Figure 5B). The median percentage of patients in the 2012
survey who declined to have their tumor analyzed at all was
25% (mean 38%±6%). Elderly patients were generally not
interested, some patients feared loss of their medical insurance if a definitive diagnosis was added to their medical
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Figure 3 Distribution of physicians according to the frequency with which they offer some type of tumor analysis (CHR3 or GEP analysis) by (A) patients undergoing
radiotherapy, or (B) patients undergoing enucleation.
Notes: Data derived from the 2014 survey. N=35.
Abbreviations: UM, uveal melanoma; CHR3, chromosome 3 analysis; GEP, gene expression profiling.
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referral to a surgeon was discussed with UM patients by
three respondents who did not offer the testing through their
own practice.
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Figure 4 Test services performed on biopsy specimens.
Notes: The majority of clinicians offered UM patients a biopsy and some form of
molecular tumor analysis. N=35.
Abbreviations: GEP, gene expression profiling; UM, uveal melanoma.

records, and some feared the biopsy procedure would hasten
tumor metastasis or cause additional morbidities. The general
absence of proven treatment interventions was also a patient
reason for declining biopsy and testing.
In the 2014 study, patients undergoing enucleation for
UM were offered some type of cytogenetic (CHR3) and/
or molecular profiling analysis (GEP) of the tumor by 83%
of the respondents (Figure 3B). Reasons given by the four
respondents who never offered these analyses were: 1) the
perceived technical difficulty of the biopsy procedure, 2) did
not believe the information would be useful to the patients,
and 3) did not believe the information would be useful to
the respondent. The option of having the testing done after
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Perhaps most importantly, 74% of respondents in the 2012
survey used the information obtained from the FNAB
specimens and cytogenetic or GEP analyses to change the
frequency of metastatic disease surveillance (Figure 6).
Twenty-one percent (8 out of 39) did not use the information
in the management of their patients, and two of these respondents referred their UM patients to oncologists, who did use
the genetic information. Four respondents who did not use the
cytogenetic data cited the current lack of effective therapeutic
options. For patients at higher risk of metastasis, 15% also
offered prophylactic therapy and 23% offered participation
in a clinical trial of an investigational therapy.
Similarly, 79% of respondents in the 2014 survey (N=33)
used the information obtained from the cytogenetic or GEP
analyses to change their clinical practice, such as adjusting
the frequency of metastatic disease surveillance, referral to
medical oncology for follow-up, and/or counseling/referral
regarding adjuvant treatment or clinical trials. Patients
with low metastatic risk, based on CHR3 or a Class 1 GEP
result, were generally assigned to less frequent (every 6 or
12 months) and less intensive clinical visits. Most respondents performed liver function tests and some type of hepatic
imaging (eg, CT, ultrasound, MRI) at least once a year
in low-risk UM patients. Only one respondent counseled
or referred low-risk patients for adjuvant clinical trials or
adjuvant treatment. In contrast, patients with high metastatic
risk, based on CHR3 or a Class 2 GEP result, were assigned
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Figure 5 Histograms illustrating the distribution of UM patients offered each type of diagnostic test.
Notes: (A) Data derived from the 2012 survey; N=37. (B) Data derived from the 2014 survey; N=34.
Abbreviations: UM, uveal melanoma; GEP, gene expression profiling.
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Figure 6 Clinical use of test data for patient management.
Notes: High-intensity surveillance of UM patients was defined as clinical visits
every 3–6 months, liver function tests every 3–6 months, and liver imaging/systemic
evaluation (eg, CT, ultrasound, MRI) every 3–6 months. Low-intensity surveillance
of UM patients was defined as clinical visits every 6–12 months and liver function
tests with some type of hepatic imaging at least once a year. Records review: N=88.
Survey: N=39.
Abbreviations: UM, uveal melanoma; CT, computed tomography; MRI, magnetic
resonance imaging.

to more frequent surveillance, with hepatic imaging or liver
function testing, often alternating quarterly. If the diagnosing physician was not an oncology specialist, then high-risk
patients were referred to one. Only one respondent said they
did not counsel or refer high-risk patients for adjuvant clinical
trials or adjuvant treatment.
When asked their thoughts concerning a low-morbidity,
low-toxicity clinical trial in the future that was designed as
an adjuvant treatment protocol, 38% believed the protocol
should be offered to all UM patients and 59% believed the
protocol should be offered only to UM patients at high risk
of tumor metastasis, based on cytogenetic or GEP analyses
(N=34). Five of the respondents (15%) who believed only
high-risk patients should be offered this type of clinical trial
would also refer patients who were classified as high-risk
based on clinical findings (ie, tumor size, cell type, etc) to
this type of clinical trial. None of the respondents would fail
to offer this alternative to their high-risk patients.
Respondents were more cautious about referring UM
patients to a high-morbidity, high-toxicity clinical trial that
was designed as an adjuvant treatment protocol (N=34). Only
9% agreed that it should be offered to all UM patients. The
majority (74%) believe that patients classified as high-risk,
based on cytogenetic or GEP analyses, should be offered

Clinical Ophthalmology 2014:8

this alternative. Six of these respondents would also offer it
to UM patients classified as high-risk based on clinical findings, and an additional two respondents would offer this type
of clinical trial to UM patients classified as high-risk based
only on clinical findings. There were also four respondents
(12%) who would not offer this type of clinical trial to any
UM patient.
Of the 191 evaluable patients in the Medicare records
review, there were 88 (46%) with documented medical treatment actions in their medical records or with documented
institutional medical policies related to surveillance plans
(Figure 1). All of the GEP Class 1 UM patients were treated
with a low-intensity surveillance plan (Figure 6). In contrast,
all of the GEP Class 2 UM patients were treated with a
high-intensity surveillance plan (P0.0001 versus Class 1
surveillance). Comments on GEP Class 1 surveillance practices from patient medical charts indicated that physicians
advised liver function tests on an annual or biannual basis,
liver imaging on an annual basis, and an annual systemic
evaluation or no surveillance at all, due to the low risk of
UM tumor metastasis. In contrast, GEP Class 2 surveillance
practices from patient medical charts indicated that physicians advised liver function tests every 3, 4, or 6 months,
and liver imaging/systemic evaluation every 3 to 6 months.
The majority of records indicated a “known policy” of more
frequent and intensive surveillance for Class 2 patients. Of
the 191 evaluable patients, there were 36 (19%) with information concerning referrals to medical oncology after initial
diagnosis. All 23 Class 2 patients were referred to medical
oncology, but none of the 13 Class 1 patients (P0.0001
versus Class 1). Similarly, only Class 2 patients were recommended for adjunctive treatment regimens.

Discussion
Concomitant with the completion of the GEP test prospective,
multicenter clinical validation study, molecular testing for
analyzing uveal melanomas has become more easily accessible over the past few years. However, the frequency of use
of these tests by ocular oncologists and the clinical application of these analyses have not been previously assessed. Our
surveys found a number of interesting observations about
current clinical practices.
In the first survey the physician respondents practiced
in North America, South America, and Europe; although, it
should be noted that a commercial GEP test is not currently
available in Europe or South America. Therefore, the 2014
survey only queried physicians with clinical practices in the
United States. In this latest survey, the respondents were
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evenly split between university-based and private practices,
and most were the only physician in their practice group to
treat UM patients. Overall, there was a wide range in the
UM caseloads among the different clinical practices. Most
handled 30–35 new cases a year, but a few had 100 or more,
for an estimated total of 1,389 in the 2014 survey. Based on
the US National Cancer Institute estimate of 4.3 new cases
of UM per million US adults a year, the most recent survey
may represent all or nearly all of the annual UM caseload in
the US in 2013.19,20 In both survey groups, more than 75%
of respondents offered molecular testing of tumor biopsy
samples to most or all of their UM patients. Safety concerns
rendered a median 10% of UM patients ineligible for a biopsy
procedure. Of the remaining patients, for whom there was
no biopsy safety concern and for whom CHR3 or GEP were
offered, the majority agreed to testing. The primary reasons
patients declined testing were that they did not want to know,
they had safety concerns about the biopsy procedure, or they
had concerns about discrimination against them by insurance
companies. Elderly patients were generally less interested.
The physicians preferred a 25 or 27 gauge needle for
FNAB of UM tumors, generally attached to a 10 cc syringe
via flexible tubing. The choice of surgical approach was usually determined by tumor location and depth, although several
respondents indicated better results in general whenever a
transscleral approach was possible. Very posterior tumors
were more likely to be approached transvitreally. There was
almost an even split between biopsy procedures performed
via a scleral window or via a full thickness sclera. When the
tumors were amenable to radiotherapy, the vast majority
were treated using brachytherapy.
As might be expected with the widespread adoption
of a new technology, the majority of physicians used the
information obtained from molecular analyses to change
patient management, specifically the frequency of metastatic
disease surveillance. The ability to rule out high-risk disease
represents an important shift in UM patient management.
According to the survey data, patients at high risk for tumor
metastases were monitored every 3–6 months, compared with
every 6–12 months for low-risk patients. The risk categories
generated from this type of testing were also used to identify
UM patients (high-risk) most likely to be referred to, and
most likely to benefit from, investigational clinical trials.
The Medicare chart and policy review results parallel the
results from the two blinded clinician surveys. Specifically,
of cases for which there was documented evidence of clinical
use of the results and/or known physician policy, 100% of
patients with a low-risk Class 1 result were managed by a

2456

submit your manuscript | www.dovepress.com

Dovepress

Dovepress

low-intensity surveillance plan that was primarily defined as
liver function tests without (or with) abdominal ultrasound at
a frequency of one or two times per year. In contrast, 100%
of patients with a high-risk Class 2 result were managed by
a high-intensity surveillance plan, primarily defined as liver
function tests and abdominal ultrasound, CT, and/or positron
emission tomography (PET) at a frequency of 2 to 4 times per
year. Additionally, more Class 2 patients received referrals to
medical oncology and/or adjuvant treatment protocols.
In agreement with the results obtained in the clinician
surveys and the Medicare chart and policy study, molecular
diagnostic testing (specifically GEP) was shown to have a
significant impact on clinical treatment strategy.4 Clinicians
used these data to “rule out” high-risk disease. When GEP
testing was used, nearly all patients with GEP Class 1 UM
were managed with a low-intensity surveillance paradigm.
In contrast, almost all Class 2 UM patients received the
standard high-intensity surveillance. Consistent with their
higher-risk disease, Class 2 UM patients were more likely
to be referred to a medical oncologist for possible clinical
trial enrollment. Thus, the GEP results may enable low-risk
patients to avoid unnecessary monitoring, inconvenience
and cost, and the adverse personal effects of worrying about
their disease. These results also provided high-risk patients
and their caregivers with important information for making
informed decisions about their own health care. Recently,
Correa and Augsburger21 reported data showing that 29%
of Class 2 GEP UM patients, but only 6% of Class 1 GEP
patients, had tumor metastases at a median follow-up time of
32.5 months (total sample size: 158). Also, GEP classification
was “substantially better” than cytologic classification for
predicting metastasis and metastatic death. Together, these
data support a recommendation for more intensive surveillance in Class 2 GEP patients, which will hopefully one day
translate into better mortality outcomes.
Overall, the data in this report support the conclusion that
molecular analysis, including GEP and chromosomal analysis,
have been widely accepted and adopted for uveal melanoma
treatment decisions. In addition to the impact on surveillance
and referral management, such information is likely to be
required for entry into future clinical trials involving adjuvant
therapy at major medical centers.22 The authors recognize that
there is no strong data suggesting that more intensive surveillance improves survival outcomes. However, the recent data
showing benefit using immunotherapy 23 and targeted therapy 24
is encouraging in that these clinical trials may advance immediate, adjuvant therapy options for UM patients over the next
few years and ultimately reduce mortality rates.
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Supplementary materials
Table S1 2012 survey questions
1 How many new cases of uveal melanoma do you see annually? (Respondent N=50)
2 Do you perform some type of cellular and/or molecular analysis of uveal malignant melanoma which requires a fine needle biopsy?
(Respondent N=50)
3 How many uveal melanoma patients (%) are not eligible for biopsy due to safety concerns? (Respondent N=37)
4 For eligible patients do you perform analysis for: (Respondent N=37)
a. Enucleated eyes only
b. All cases
5 What percent of uveal melanoma cases do you offer cytogenetic (chromosome 3) testing? (Respondent N=37)
6 What percent of uveal melanoma cases do you offer molecular testing (DecisionDx-UM gene expression profile)? (Respondent N=37)
7 How many biopsies for uveal melanoma do you perform annually? (Respondent N=37)
8 In what % of cases do you employ use of a vitrector for biopsy procedures? (Respondent N=35)
9 What size needle gauge do you use to biopsy the tumor? (Respondent N=35)
10 Do you utilize flexible tubing between the needle hub and the syringe to stabilize the needle position? (Respondent N=27)
11 What size syringe do you use in order to create vacuum? (Respondent N=27)
12 Do you perform the biopsy via a scleral window or via full thickness sclera? (Respondent N=35)
13 What percent of biopsies are performed transscleral? (Respondent N=35)
14 What percent of biopsies are performed transvitreal? (Respondent N=35)
15 If you perform both transscleral and transvitreal biopsies, what factors contribute to your decision process? (Respondent N=35)
16 After the biopsy is performed do you “seal” the biopsy site? (Respondent N=35)
17 Is the biopsy performed... (Respondent N=35)
a. At the time of plaque placement, enucleation or clip placement
b. As a separate procedure
18 How many tumor sites do you biopsy? (Respondent N=24)
19 What testing do you perform with your biopsy material? (Respondent N=35)
20 What fixative do you use (ex, fixative provided by processing lab, cytolyte, formalin)? (Respondent N=35)
21 Do you offer all patients biopsy and analysis of the tumor? (Respondent N=39)
22 What percentage of patients decline the offer for testing? (Respondent N=39)
23 What reasons are given for declining testing? (Respondent N=39)
24 How do you use the information clinically? (Respondent N=39)
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Table S2 2014 survey questions
1 Did you participate in the July 2012 survey that Dr Aaberg distributed in preparation for the 2012 Retina sub-specialty day presentation?
(Respondent N=35)
2 Are you: (Respondent N=32)
• University based
• Private practice
• Government based (ex: Veterans Administration)
• Other ____________
3 Within your practice group, how many physicians treat primary uveal melanoma? (Respondent N=35)
4 How many new cases of uveal melanoma do you personally see annually (eg, if in a practice group with more than one physician who treats
uveal melanoma, only include your direct new cases)? (Respondent N=35)
5 For patients amenable to radiotherapy, do you use: (Respondent N=34)
• Brachytherapy
• Proton Beam
• I have access to both modalities and use both equally
• I have access to both modalities and use Proton Beam principally
• I have access to both modalities and use Brachytherapy principally
• Other ____________
6 For patients undergoing radiotherapy for ocular melanoma, do you offer some type of cytogenetic (chromosome 3) and/or molecular profiling
analysis (the gene expression profile test) of the tumor which requires a biopsy? (Respondent N=35)
• Never or rarely
• Less than 33%
• 33%–85%
• Nearly always
7 If you answered “Never or rarely” to question #5, you do not offer testing because (please check all answers that apply): (Respondent N=5)
• Safety concerns, such as increased risk of orbital seeding or risk of vision loss due to hemorrhage
• Perceive the biopsy procedure as technically difficult
• The information obtained will not alter my management decisions
• Do not believe the information provided to be useful to me
• Do not believe the information provided to be useful to the patient
• Believe the testing should only be used in an investigational setting
• Other ____________
8 For patients undergoing enucleation for ocular melanoma, do you offer some type of cytogenetic (chromosome 3 – disomy or monosomy) and/
or molecular profiling analysis (the gene expression profile test – Class 1 or Class 2) of the tumor? (Respondent N=35)
• Never or rarely
• Less than 33%
• 33%–85%
• Nearly always
9 If you answered “Never or rarely” to question #7 you do not offer testing because (please check all answers that apply): (Respondent N=2)
• Safety concerns, such as increased risk of orbital seeding or risk of vision loss due to hemorrhage
• Perceive the biopsy procedure as technically difficult
• The information obtained will not alter my management decisions
• Do not believe the information provided to be useful to me
• Do not believe the information provided to be useful to the patient
• Believe the testing should only be used in an investigational setting
• Other ____________
10 If you do not offer any form of testing in any case, do you still discuss the option with the patient and refer the patient to a center that does
perform testing? (Respondent N=31)
• Yes
• No
• Does not apply, because I do offer testing
11 If you do not offer any form of testing in any case, please complete this question but you do not have to continue the questionnaire. Will you
consider performing testing in the future? If so, what would have to occur? (Respondent N=26)
• No
• Yes, ____________
• Does not apply, because I do offer testing

(Continued)
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Table S2 (Continued)
12 What percentage of your radiotherapy patients are not eligible for biopsy due to safety concerns related to the biopsy procedure, such as tumor
location or small size? (Respondent N=32)
13 Of the remaining radiotherapy patients for whom there is no biopsy safety concern and for whom you offer cytogenetic or gene expression
profiling analysis of the tumor, what percentage agrees to testing? (Respondent N=32)
14 What is the principle reason that patients decline testing (select only what you consider the number one reason even though other reasons may
apply)? (Respondent N=26)
• Safety concerns, for example: increased risk of orbital seeding, risk of vision loss due to hemorrhage.
• The patient “does not want to know”
• C
 oncerned that the information may be used against them, example: disability or life insurance company may deem the patients as
“uninsurable” if they have a “high-risk” tumor.
• Cost of testing
• Other ____________
15 Which testing do you offer? (check all that apply) (Respondent N=34)
• Cytogenetics (chromosome 3 analysis)
• Molecular profiling diagnostics (the gene expression profile test)
• Other ____________
16 For those patients that have testing, what percent do you offer cytogenetic (chromosome 3) testing? (Respondent N=32)
17 For those patients that have testing, what percent do you offer molecular profiling diagnostics (the gene expression profile test)? (Respondent N=34)
18 For those patients who have testing performed, do you use the information clinically (such as metastatic surveillance approach, referral to
medical oncology for follow-up, or counsel/refer regarding adjuvant treatment or adjuvant clinical trials)? (Respondent N=33)
19 If you answered “Yes” to question 18 regarding metastatic surveillance approach, please describe your general approach (eg, frequency and type
of testing or imaging) for patients with low risk Class 1/disomy 3 test results. (Respondent N=24)
20 If you answered “Yes” to question 18 regarding metastatic surveillance approach, please describe your general approach (eg, frequency and type
of testing or imaging) for patients with high-risk Class 2/monosomy 3 test results. (Respondent N=24)
21 If you answered “Yes” to question 18 regarding counseling regarding adjuvant treatment options or adjuvant clinical trials (Respondent N=27):
• Do you counsel or refer low risk Class 1/disomy 3 patients for adjuvant clinical trials or adjuvant treatment?
• Do you counsel or refer high-risk Class 2/monosomy 3 patients for adjuvant clinical trials or adjuvant treatment?
22 Thinking about future clinical trials, if a low morbidity risk adjuvant treatment protocol (that is, a treatment that has a relatively low toxicity or
side effect profile) was available for uveal melanoma patients, do you believe (Respondent N=34):
• The protocol should be offered to all uveal melanoma patients
• The protocol should be offered only to patients with high-risk features based on clinical findings (ie, tumor size, cell type, etc).
• The protocol should be offered only to patients with high-risk features based on gene expression profile diagnostics and/or cytogenetics.
• The protocol should not be offered to any patient.
23 Thinking about future clinical trials, if a high morbidity risk adjuvant treatment protocol (that is, a treatment that has a relatively high toxicity or
side effect profile) was available for uveal melanoma patients, do you believe (Respondent N=34):
• The protocol should be offered to all uveal melanoma patients
• The protocol should be offered only to patients with high-risk features based on clinical findings (ie, tumor size, cell type, etc).
• The protocol should be offered only to patients with high-risk features based on molecular diagnostics and/or cytogenetics.
• The protocol should not be offered to any patient.
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